| Drug NDC: | 0074-2625 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Mavyret |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Glecaprevir And Pibrentasvir |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Abbvie Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Tablet, Film Coated |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | GLECAPREVIR - 100 mg/1 PIBRENTASVIR - 40 mg/1 |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 03 Aug, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 27 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Application Number: | NDA209394 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | AbbVie Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| RxCUI: | 1940703 1940709 2557906 2557910 |
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| UPC: | 0300742625807 |
| UPC stands for Universal Product Code. | |
| NUI: | N0000182639 N0000182638 N0000185503 N0000190113 N0000190107 N0000190108 N0000190114 N0000182138 N0000191272 N0000191256 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | K6BUU8J72P 2WU922TK3L |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | HCV NS3/4A Protease Inhibitors [MoA] P-Glycoprotein Inhibitors [MoA] Breast Cancer Resistance Protein Inhibitors [MoA] Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA] Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] Cytochrome P450 3A Inhibitors [MoA] Cytochrome P450 1A2 Inhibitors [MoA] UGT1A1 Inhibitors [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] Hepatitis C Virus NS5A Inhibitor [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class: | Breast Cancer Resistance Protein Inhibitors [MoA] Cytochrome P450 1A2 Inhibitors [MoA] Cytochrome P450 3A Inhibitors [MoA] HCV NS3/4A Protease Inhibitors [MoA] Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] Hepatitis C Virus NS5A Inhibitor [EPC] Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA] Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] P-Glycoprotein Inhibitors [MoA] UGT1A1 Inhibitors [MoA] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 0074-2625-01 | 1 DOSE PACK in 1 CARTON (0074-2625-01) / 3 TABLET, FILM COATED in 1 DOSE PACK | 03 Aug, 2017 | N/A | No |
| 0074-2625-28 | 4 CARTON in 1 CARTON (0074-2625-28) / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK | 03 Aug, 2017 | N/A | No |
| 0074-2625-56 | 2 CARTON in 1 CARTON (0074-2625-56) / 4 CARTON in 1 CARTON / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK | 03 Aug, 2017 | N/A | No |
| 0074-2625-80 | 84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-80) | 27 Jun, 2019 | 23 Apr, 2023 | No |
| 0074-2625-84 | 84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84) | 22 Jun, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.